Global Intravenous Immunoglobulin (IVIG) Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

The global intravenous immunoglobulin market size was valued at $9,356 million in 2018, and is projected to reach $15,964 million by 2026, registering a CAGR of 7.8% from 2019 to 2026.

The global IVIG market is driven by factors such as high prevalence of diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia coupled with surge in geriatric population and rise in the number of hemophilic patients. In addition, increase in production of immunoglobulin with better plasma quality using advanced purification techniques is expected to supplement the market growth. On the other hand, technological advancements in IVIG products are anticipated to provide lucrative opportunities in the market in near future. However, stringent government regulations towards IVIG products and side effects associated with the use of IVIG impede the growth of the market.

The report analyzes and forecasts the intravenous immunoglobulin market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global intravenous immunoglobulin market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the intravenous immunoglobulin market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of intravenous immunoglobulin market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

The main objective of this report is to aid the user in understanding the market as a whole, its definitions, segmentation, market potential, influential trends, and the barriers that it is facing. Meticulous research and analysis were an important part of the report preparation. Those reading the report will be able to get a detailed understanding about the market. Industry experts have verified and checked the data and information that have been taken from credible sources like websites, annual reports of companies, journals, and other resources. In order give the facts and data a pictorial form, diagrams, graphs, pie charts, and other representations have been used. That augments the visual appeal of the report and makes understanding it much easier.

Competitive Landscape is the most valuable part of this report

The report provides extensive competitive analysis and profiles of key market players that includes Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, and Bayer Healthcare.

Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

Key financial developments of a particular company and product & company overview are some of the elements that help in acquiring information about top vendors in the market.  This particular section has also included a SWOT analysis of the companies featured in the report. This will help the audience in knowing about opportunities, strengths, threats and weaknesses that are facing by the key vendors in the chemical and material industry across the world. As the competitive landscape is the most valuable part of any report, it consists of all the required information for the detailed study of top players functioning in the industries. It is also an interesting part to find how exactly these key manufacturers implement various strategies to secure the top rank in the industry. Such an in-depth information is useful for the new entrants into the industry as they would be able to learn a bit from these key vendors. Similarly, the information provided in the research report will also be valuable for the renowned key players as well, as they come to know the strategies of their counterparts to sustain in the competitive industry.

Segmentation

By Application
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunodeficiency Disease
Myasthenia Gravis
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Inflammatory Myopathies
Specific Antibody Deficiency
Guillain?Barré Syndrome
Others

By Type
IgG
IgA
IgM
IgE
IgD

Report coverage

  • Analysis Period: 2015 – 2026
  • Base Year: 2018
  • Forecast Data: 2019 – 2026
  • Regional Scope: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • Report Coverage: Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

  • To analyze and study the global intravenous immunoglobulin capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026);
  • Focuses on the key intravenous immunoglobulin manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Section 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Section 2: EXECUTIVE SUMMARY

2.1. CXO perspective

Section 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Overview of Immunoglobulin

3.2.1. Patented products
3.2.2. Epidemiology and economic burden of chronic conditions

3.3. Key findings

3.3.1. Top Investment Pockets

3.4. Porter’s five forces analysis
3.5. Value chain analysis

3.5.1. Primary activities
3.5.2. Support activities

3.6. Market share analysis, 2017
3.7. Product scenario in intravenous immunoglobulin market
3.8. Government regulations and reimbursements

3.8.1. U.S.
3.8.2. Europe
3.8.3. France
3.8.4. Germany
3.8.5. Italy
3.8.6. China
3.8.7. Japan
3.8.8. India

3.9. Indications for immunoglobulin

3.9.1. U.S. FDA indications
3.9.2. EMA

3.10. Component analysis of immunoglobulin G (IgG)

3.10.1. IgG1
3.10.2. IgG2
3.10.3. IgG3
3.10.4. IgG4

3.11. Market dynamics

3.11.1. Drivers

3.11.1.1. Rise in prevalence of immunodeficiency diseases
3.11.1.2. Increase in adoption of immunoglobulin treatment
3.11.1.3. Growth in incidence of bleeding disorders

3.11.2. Restraints

3.11.2.1. Stringent government regulations
3.11.2.2. High cost of therapy

3.11.3. Opportunities

3.11.3.1. Opportunities in emerging economies
3.11.3.2. Development of cost-effective therapeutics through large-scale production

Section 4: IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Hypogammaglobulinemia

4.2.1. Market size and forecast

4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)

4.3.1. Market size and forecast

4.4. Primary immunodeficiency diseases

4.4.1. Market size and forecast

4.5. Myasthenia Gravis

4.5.1. Market size and forecast

4.6. Multifocal motor neuropathy

4.6.1. Market size and forecast

4.7. Idiopathic thrombocytopenic purpura (ITP)

4.7.1. Market size and forecast

4.8. Inflammatory myopathies

4.8.1. Market size and forecast

4.9. Specific antibody deficiency

4.9.1. Market size and forecast

4.10. Guillain-Barre syndrome

4.10.1. Market size and forecast

4.11. Others

4.11.1. Market size and forecast

Section 5: IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1. Overview

5.1.1. IGG

5.1.1.1. Key market trends

5.1.2. Clinical interpretations
5.1.3. IGA

5.1.3.1. Key Market Trends

5.1.4. Clinical interpretation
5.1.5. IGM

5.1.5.1. Key Market Trends

5.1.6. Clinical interpretation
5.1.7. IGE

5.1.7.1. Key Market Trend

5.1.8. Clinical interpretation
5.1.9. IGD

5.1.9.1. Key Market Trends

5.1.10. Clinical interpretation

Section 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key trends and opportunities
6.2.2. North America market size & forecast, by application
6.2.3. North America market size & forecast, by country

6.2.3.1. U.S. market size & forecast
6.2.3.2. Canada market size & forecast
6.2.3.3. Mexico market size & forecast

6.3. Europe

6.3.1. Key trends and opportunities
6.3.2. Europe market size & forecast, by application
6.3.3. Europe market size & forecast for immunoglobulin market, by country

6.3.3.1. Germany market size & forecast
6.3.3.2. France market size & forecast
6.3.3.3. UK market size & forecast
6.3.3.4. Italy market size & forecast
6.3.3.5. Austria market size & forecast
6.3.3.6. Russia market size & forecast
6.3.3.7. Rest of Europe market size & forecast

6.4. Asia-Pacific

6.4.1. Key trends and opportunities
6.4.2. Asia-Pacific market size & forecast, by application
6.4.3. Asia-Pacific market size & forecast, by country

6.4.3.1. Australia market size & forecast
6.4.3.2. China market size & forecast
6.4.3.3. India market size & forecast
6.4.3.4. Japan market size & forecast
6.4.3.5. Rest of Asia-Pacific market size & forecast

6.5. LAMEA

6.5.1. Key trends and opportunities
6.5.2. LAMEA market size & forecast, by application
6.5.3. LAMEA market size & forecast, by country

6.5.3.1. Brazil market size & forecast
6.5.3.2. Saudi Arabia market size & forecast
6.5.3.3. Argentina market size & forecast
6.5.3.4. Turkey market size & forecast
6.5.3.5. Rest of LAMEA market size & forecast

Section 7: COMPANY PROFILES

7.1. BAXTER INTERNATIONAL INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. BAYER AG

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. BIOTEST AG

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. CHINA BIOLOGIC PRODUCTS, INC.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance

7.5. CSL LIMITED

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance

7.6. GRIFOLS S.A.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. KEDRION BIOPHARMA INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. LFB SA (LFB BIOTECHNOLOGIES SAS)

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. OCTAPHARMA AG

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance

7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers